Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations


50.25   -2.44 (-4.63%) 02-24 16:00
Open: 50.27 Pre. Close: 52.69
High: 51.13 Low: 48.93
Volume: 702,016 Market Cap: 1872M
Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 51.186 - 51.603 51.603 - 51.883
Low: 48.082 - 48.533 48.533 - 48.836
Close: 49.649 - 50.36 50.36 - 50.838

Technical analysis

as of: 2020-02-24 4:46:50 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 64.20     One year: 74.99
Support: Support1: 47.14    Support2: 42.30
Resistance: Resistance1: 54.97    Resistance2: 64.20
Pivot: 51.32
Moving Average: MA(5): 52.82     MA(20): 49.46
MA(100): 42.24     MA(250): 45.05
MACD: MACD(12,26): 2.26     Signal(9): 2.32
Stochastic oscillator: %K(14,3): 75.61     %D(3): 84.04
RSI: RSI(14): 53.81
52-week: High: 63.21  Low: 30.38  Change(%): -5.0
Average Vol(K): 3-Month: 45592  10-Days: 36096

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
RGNX has closed above bottom band by 39.3%. Bollinger Bands are 27.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 10 Feb 2020 16:27:00 +0000
Here's Why Adverum Biotechnologies Is Soaring Today

Mon, 28 Oct 2019 05:00:00 +0000
Pfizer Takes Aim at Regeneron, and UnitedHealth's Earnings Update

Mon, 14 Oct 2019 19:20:27 +0000
Notable Monday Option Activity: RGNX, ICUI, SAM

Sun, 13 Oct 2019 17:00:00 +0000
3 Beaten-Up Biotechs -- Are They Buys?

Fri, 11 Oct 2019 20:09:10 +0000
Big Pharma Has Mad Love For These 2 Biotechs

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 36.87
Shares Float (M) 26.97
% Held by Insiders 14.99
% Held by Institutions 85.64
Shares Short (K) 4130
Shares Short P. Month (K)

Stock Financials

EPS -1.750
Book Value (p.s.) 12.710
PEG Ratio -11.34
Profit Margin -99.57
Operating Margin -165.35
Return on Assets (ttm) -13.0
Return on Equity (ttm) -13.3
Qtrly Rev. Growth 177.0
Gross Profit (p.s.) 3.390
Sales Per Share
EBITDA (p.s.) -2.704
Qtrly Earnings Growth
Operating Cash Flow (M) -86.34
Levered Free Cash Flow (M) -55.59

Stock Valuations

P/E -28.71
P/E Growth Ratio -0.05
P/BV 3.95
P/S 28.55
P/CF -21.46

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.